| Semaglutide Effects on Sperm Concentration in Overweight Infertile Men | Semaglutide | Phase 2 | Not yet recruiting | Copenhagen University Hospital at Herlev | Nov 18, 2026 |
| Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension | Tirzepatide | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | Nov 18, 2026 |
| A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or Obesity | Semaglutide | Phase 1 | Not yet recruiting | Novo Nordisk A/S | Nov 17, 2026 |
| Fighting Osteoporosis With Risedronate Co-Therapy During Incretin | Tirzepatide | Phase 3 | Not yet recruiting | Wake Forest University Health Sciences | Nov 17, 2026 |
| A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity | Survodutide | Phase 1 | Not yet recruiting | Boehringer Ingelheim | Nov 16, 2026 |
| Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults | Semaglutide | Phase 1 | Not yet recruiting | Korea United Pharm. Inc. | Nov 13, 2026 |
| A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both | Semaglutide | Phase 3 | Not yet recruiting | Novo Nordisk A/S | Nov 12, 2026 |
| AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both | Semaglutide | Phase 3 | Not yet recruiting | Novo Nordisk A/S | Nov 12, 2026 |
| Molecular and Microbiome Changes During Tirzepatide Treatment and Resistance Training in Obesity | Tirzepatide | — | Not yet recruiting | Technical University of Munich | Nov 12, 2026 |
| Breath Acetone During Tirzepatide Treatment and Resistance Training in Adults With Obesity | Tirzepatide | — | Not yet recruiting | Technical University of Munich | Nov 12, 2026 |
| 24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor | Dulaglutide, Liraglutide, Semaglutide, Tirzepatide | Not applicable | Not yet recruiting | Portuguese Oncology Institute, Coimbra | Nov 10, 2026 |
| Functional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight Loss | Tirzepatide | — | Not yet recruiting | Technical University of Munich | Nov 10, 2026 |
| Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes | Semaglutide, Tirzepatide | Not applicable | Not yet recruiting | German Diabetes Center | Nov 9, 2026 |
| Ocular Changes in Patients Using Tirzepatide or Semaglutide | Semaglutide, Tirzepatide | — | Recruiting | Istanbul University | Nov 9, 2026 |
| Changes in Body Composition Following Pharmacological Treatment for Obesity. | Liraglutide | — | Enrolling by invitation | Hospital San Carlos, Madrid | Nov 2, 2026 |
| A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease | Exenatide, Liraglutide, Lixisenatide | Phase 2 | Active, not recruiting | Beijing University of Chinese Medicine | Oct 30, 2026 |
| Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity | Liraglutide | — | Recruiting | Yuzuncu Yil University | Oct 28, 2026 |
| A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy | Dulaglutide, Exenatide, Liraglutide, Lixisenatide | — | Not yet recruiting | Novartis Pharmaceuticals | Oct 19, 2026 |
| Hypothalamic GLP-1 Response in Healthy Weight and Obesity | Avexitide | Not applicable | Recruiting | University of Copenhagen | Oct 2, 2026 |
| SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Survodutide | Phase 3 | Recruiting | Boehringer Ingelheim | Oct 2, 2026 |
| ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease | Survodutide | Phase 3 | Not yet recruiting | Boehringer Ingelheim | Sep 30, 2026 |
| SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight | Survodutide | Phase 3 | Recruiting | Boehringer Ingelheim | Sep 30, 2026 |
| Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization | Exenatide | Not applicable | Recruiting | Peking Union Medical College Hospital | Sep 9, 2026 |
| Islet Function in Gestational Diabetes | Avexitide | Phase 1 | Recruiting | Mayo Clinic | Sep 8, 2026 |
| GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry | Dulaglutide, Liraglutide | — | Not yet recruiting | Miedziowe Centrum Zdrowia SA | Aug 26, 2026 |
| A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity | Survodutide | Phase 1 | Active, not recruiting | Boehringer Ingelheim | Aug 17, 2026 |
| A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar | Survodutide | Phase 3 | Recruiting | Boehringer Ingelheim | Aug 10, 2026 |
| Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists | Dulaglutide, Exenatide, Liraglutide | — | Recruiting | Ohio State University | Jul 14, 2026 |
| Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus | Dulaglutide | Phase 2 | Not yet recruiting | ProGen. Co., Ltd. | Jul 1, 2026 |
| A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes | Dulaglutide | Phase 3 | Recruiting | Eli Lilly and Company | Jun 25, 2026 |
| Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes | Liraglutide | — | Enrolling by invitation | Indiana University | Jun 10, 2026 |
| Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | Dulaglutide | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wannan Medical College | Apr 17, 2026 |
| Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis | Exenatide | Phase 2 | Recruiting | Johns Hopkins University | Mar 27, 2026 |
| Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight | Retatrutide | Phase 2 | Recruiting | Hudson Biotech | Mar 12, 2026 |
| A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body | Survodutide | Phase 1 | Active, not recruiting | Boehringer Ingelheim | Feb 12, 2026 |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Retatrutide | Phase 3 | Active, not recruiting | Eli Lilly and Company | Jan 22, 2026 |
| A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus | Exenatide | Early phase 1 | Recruiting | The First Affiliated Hospital of Henan University of Science and Technology | Jan 16, 2026 |
| Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists | Dulaglutide | Phase 4 | Active, not recruiting | MaryAnn Banerji | Jan 8, 2026 |
| Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD | Exenatide | — | Recruiting | Cardenal Herrera University | Dec 30, 2025 |
| Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents | Lixisenatide | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | Dec 29, 2025 |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Retatrutide | Phase 3 | Active, not recruiting | Eli Lilly and Company | Nov 18, 2025 |
| Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease | Survodutide | Phase 2 | Not yet recruiting | University Medical Center Groningen | Oct 3, 2025 |
| Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH) | Albiglutide, Exenatide, Lixisenatide | — | Active, not recruiting | Ohio State University | Sep 23, 2025 |
| Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | Lixisenatide | Phase 4 | Not yet recruiting | Yanbing Li | Sep 15, 2025 |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Retatrutide | Phase 3 | Recruiting | Eli Lilly and Company | Sep 10, 2025 |
| Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes | Lixisenatide | Phase 4 | Enrolling by invitation | Medical University of Warsaw | Aug 12, 2025 |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | Retatrutide | Phase 3 | Active, not recruiting | Eli Lilly and Company | Jun 24, 2025 |
| POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS | Avexitide | Not applicable | Recruiting | University of Copenhagen | Jun 13, 2025 |
| A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | Retatrutide | Phase 1 | Active, not recruiting | Eli Lilly and Company | May 21, 2025 |
| The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans | Avexitide | Phase 2 | Not yet recruiting | Mayo Clinic | May 15, 2025 |
| The Role of Islet GLP-1 in the Pathogenesis of Prediabetes | Avexitide | Phase 2 | Recruiting | Mayo Clinic | May 13, 2025 |
| The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. | Avexitide | Not applicable | Not yet recruiting | Bispebjerg Hospital | Mar 12, 2025 |
| A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | Retatrutide | Phase 3 | Active, not recruiting | Eli Lilly and Company | Mar 5, 2025 |
| Avexitide for Treatment of Post-Bariatric Hypoglycemia | Avexitide | Phase 3 | Active, not recruiting | Amylyx Pharmaceuticals Inc. | Dec 24, 2024 |
| iGlarLixi CGM Study in Chinese T2D Individuals After OADs | Lixisenatide | Phase 4 | Recruiting | Sanofi | Nov 4, 2024 |
| A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Retatrutide | Phase 3 | Active, not recruiting | Eli Lilly and Company | Oct 28, 2024 |
| Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study | Albiglutide, Lixisenatide | — | Active, not recruiting | Brigham and Women's Hospital | Feb 2, 2022 |
| The Effects of Bariatric Surgeries on Glucose Metabolism | Avexitide | Early phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | Jul 6, 2016 |